• M H Ereth, W C Oliver, F M Beynen, C J Mullany, T A Orszulak, P J Santrach, D M Ilstrup, A L Weaver, and K R Williamson.
• Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota 55905.
• Anesthesiology. 1993 Sep 1; 79 (3): 540-7; discussion 27A.

BackgroundPatients undergoing cardiac surgery employing cardiopulmonary bypass frequently require transfusion of homologous blood products and, therefore, are exposed to the risk of transfusions. Autologous platelet-rich plasma administration may reduce homologous transfusion and attendant risks.MethodsIn a blinded, randomized fashion, patients undergoing repeat sternotomy and valvular surgery received either a sham product (n = 28) or autologous platelet-rich plasma (n = 28) at the conclusion of cardiopulmonary bypass. Perioperative blood loss, coagulation profiles, and transfusion requirements were compared between the two groups.ResultsIn the first 24 h postoperatively, both the platelet-rich plasma and sham groups received a median of 10.5 units of homologous blood products. Total median perioperative homologous transfusion requirements were 13 and 11.5 units for the platelet-rich plasma and sham groups, respectively. There was no significant difference in intraoperative or postoperative bleeding between the groups.ConclusionsAutologous platelet-rich plasma did not reduce perioperative bleeding or transfusion requirements in repeat valvular surgery.

15 keywords...

hide…